IKNA IKNA

Ikena Oncology Stock Price

10.76
0.00 (0.0%)
10.76
Volume 0
Bid Price 6.45
Ask Price 17.50
News -
Day High

Low
9.63

52 Week Range

High
37.61

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Ikena Oncology Inc IKNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 10.76 07:00:17
Open Price Low Price High Price Close Price Prev Close
10.76
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 10.76 USD

Period:

Draw Mode:

Ikena Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 386.36M 35.91M 29.97M $ 9.19M $ - -3.16 -2.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 463.66k 0.20%

more financials information »

Ikena Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IKNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.2611.5210.5310.88121,575-0.50-4.44%
1 Month14.1514.5810.5311.99123,378-3.39-23.96%
3 Months11.8117.5010.5313.69170,971-1.05-8.89%
6 Months10.8717.509.6313.20117,411-0.11-1.01%
1 Year22.4037.619.6316.10158,041-11.64-51.96%
3 Years22.4037.619.6316.10158,041-11.64-51.96%
5 Years22.4037.619.6316.10158,041-11.64-51.96%

Ikena Oncology Description

Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.


Your Recent History
NASDAQ
IKNA
Ikena Onco..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.